Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics ( (AU:PER) ) has provided an update.
Percheron Therapeutics has launched a non-renounceable pro-rata entitlement offer, allowing eligible shareholders to subscribe for two new shares for every five existing shares at an issue price of $0.005, with one free attaching option for every two new shares subscribed. The company will also run a shortfall offer on the same terms for any unsubscribed securities, with directors retaining discretion to scale back allocations, and option holders must first exercise their options by the record date if they wish to participate, potentially broadening the shareholder base and strengthening the company’s capital position.
The entitlement offer includes new options expiring two years from issue with an exercise price of $0.01, providing additional potential future funding if exercised. By structuring the raise with both an entitlement and shortfall offer, Percheron aims to maximise subscription uptake while offering existing investors the opportunity to increase their holdings and influence, which may impact control dynamics and liquidity in the company’s shares over time.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an Australia-based biotechnology company listed on the ASX under ticker PER. The company focuses on developing therapeutic products, operating within the healthcare and life sciences sector and targeting investors interested in early-stage medical innovation.
Technical Sentiment Signal: Sell
Current Market Cap: A$6.52M
See more data about PER stock on TipRanks’ Stock Analysis page.